Clinical Trials on Skin Diseases, Vesiculobullous

Total 382219 results

Eli Lilly and Company

Completed

A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris

Psoriasis

China
GlaxoSmithKline

Completed

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repeat Doses of GSK2982772 in Subjects With Psoriasis

Psoriasis

Canada
University of California, San Francisco

Terminated

Excimer Laser Phototherapy Outcomes in the Treatment of Psoriasis (Photos)

Psoriasis

United States
Celgene

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis

Psoriasis

United States, Canada
Amgen

Completed

A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in Belgium (OTELO)

Psoriasis

Belgium
AbbVie

Completed

Real-World Outcome of Psoriasis Subjects in Korea on Adalimumab (RAPSODI)

Psoriasis

Korea, Republic of
Bristol-Myers Squibb

Completed

An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants

Psoriasis

United States
Psoriasis Treatment Center of Central New Jersey
Janssen Scientific Affairs, LLC

Completed

An Outcomes Study to Determine the Reasons Patients on Biologic Therapy Discontinue Treatment and Fail to Follow-up With Their Providers

Psoriasis

United States
University of Michigan
AbbVie

Completed

Skin Tape Harvesting for Transcriptomics Analysis

Psoriasis

United States
Janssen-Cilag G.m.b.H

Completed

A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (POLARIS)

Psoriasis

Germany
Bausch Health Americas, Inc.

Terminated

Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-1)

Psoriasis

United States, Germany, Poland, Switzerland, France, Canada
AbbVie (prior sponsor, Abbott)
Cato Research; JSS Medical Research Inc.

Completed

Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis (Complete-PS)

Psoriasis

Canada
Eli Lilly and Company

Completed

A Study in Japanese Participants With Moderate-to-Severe Psoriasis (UNCOVER-J)

Psoriasis

Japan
Zagazig University

Unknown

Turmeric Based Therapy in the Treatment of Psoriasis: A Clinical Trial

Psoriasis
Bausch Health Americas, Inc.

Terminated

Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis

Psoriasis

United States, Australia, France, Canada, Denmark
Amgen

Completed

Etanercept (Enbrel®) in Psoriasis - Pediatrics

Psoriasis
Cairo University

Unknown

The Effect of NB-UVB on Interleukin-36 Levels in Psoriasis

Psoriasis
Amgen

Completed

Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis

Psoriasis

Australia, Canada, Hungary
Assiut University

Unknown

Serum Level of Bioactive Mediators and Urinary Biopyrins in Psoriasis

Psoriasis
Eli Lilly and Company

Completed

A Study of Ixekizumab in Participants With Plaque Psoriasis

Psoriasis

United States
Janssen Biotech, Inc.

Completed

Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database

Psoriasis
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Clinical Effects of Navarixin in Participants With Psoriasis (MK-7123-009)

Psoriasis
Vitae Pharmaceuticals Inc., an Allergan affiliate

Completed

An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers and Psoriatic Patients

Psoriasis

United States
Janssen Research & Development, LLC

Completed

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

Psoriasis

United States, Canada, Poland
University of California, Davis
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Withdrawn

Role of Chemokine and Chemokine Receptor in Psoriasis

Psoriasis

United States
Wake Forest University Health Sciences

Completed

Nurse Education in Subjects With Psoriasis Undergoing Treatment With Adalimumab

Psoriasis

United States
Amgen
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis
Amgen

Completed

Observational Safety Study of Etanercept (Enbrel) for Treatment of Psoriasis

Psoriasis
Tianjin Hemay Bio-Tech Co., Ltd

Completed

Safety and Pharmacokinetics of Hemay005 In Healthy Male Subjects

Psoriasis

China
Promius Pharma, LLC

Completed

A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis

Psoriasis

United States
Prothena Biosciences Limited

Completed

Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis

Psoriasis

United States
Kang Stem Biotech Co., Ltd.

Unknown

Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis

Psoriasis

Korea, Republic of
Lina R. Khoury

Unknown

A Nurse-led Individualized Educational Intervention

Psoriasis

Denmark
GlaxoSmithKline
PPD; ERT: Clinical Trial Technology Solutions; Q2 Solutions

Withdrawn

GSK2894512 Vehicle-Controlled Study for Adult Plaque Psoriasis

Psoriasis
AbbVie

Terminated

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis

Psoriasis

United States
Stiefel, a GSK Company
GlaxoSmithKline

Completed

Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compared to Vehicle Foam

Psoriasis

United States
Janssen Research & Development, LLC

Completed

A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab (NAVIGATE)

Psoriasis

United States, Poland, United Kingdom, Germany, Taiwan, Spain, Australia, Canada, Korea, Republic of, Russian Federation
Centocor, Inc.

Completed

A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis

Psoriasis

United States
Janssen Pharmaceutical K.K.

Completed

A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

Japan
Illumicure Inc

Unknown

Evaluation of Efficacy, Duration of Remission and Safety of a Light and Occlusive Patch Therapy for Plaque Psoriasis

Psoriasis

United States
Genentech, Inc.

Completed

A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp (SCALP)

Psoriasis
Taro Pharmaceuticals USA

Completed

Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis

Psoriasis
Eli Lilly and Company

Completed

A Safety Study of Mirikizumab (LY3074828)

Psoriasis

Canada
GlaxoSmithKline

Completed

Study of Safety and Efficacy of Topical GSK2981278 Ointment in Plaque Psoriasis

Psoriasis

Germany
Merck Sharp & Dohme LLC

Completed

The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED)

Psoriasis
University College Dublin

Completed

Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP) (DINUP)

Psoriasis

Ireland
Bausch Health Americas, Inc.

Completed

Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects

Psoriasis

United States, Australia, New Zealand
Bayer

Completed

BAY1003803 Formulation Comparison in Open Psoriasis Plaque Test

Psoriasis

Germany
Genentech, Inc.

Completed

A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands and/or Feet

Psoriasis
Janssen Biotech, Inc.

Completed

A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis (PSTELLAR)

Psoriasis

United States

3

Subscribe